Document Detail


Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: the lower, the better; is it true for Asians? (Pro).
MedLine Citation:
PMID:  20671371     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Large clinical trials have elucidated that lipid-lowering therapy using statins reduces cardiovascular events in patients with coronary artery disease (CAD). The benefit of statin therapy is proportional to the achieved low-density lipoprotein cholesterol level (LDL-C) up to 70 mg/dl. On the basis of this evidence, the American Heart Association and American College of Cardiology offer an optimal LDL-C goal of <70 mg/dl for patients with a very high risk of CAD. In addition, with regard to acute coronary syndrome (ACS), which has a high risk for future cardiac events because of the presence of vulnerable plaque, intensive lipid-lowering therapy from the early stage is the standard treatment. On the other hand, the mechanism of inhibition of cardiac events by statins is thought to be predominantly based on stabilization of plaque, but research on the role of plaque regression is also advancing. The clinical significance of intensive lipid-lowering therapy using statins will be discussed from the following standpoints: (1) large-scale clinical trials around the world; (2) the relationship with plaque regression and stabilization; (3) the relationship with the diverse effects of statins; and (4) evidence generated from Japanese patients.
Authors:
Katsumi Miyauchi; Hiroyuki Daida
Publication Detail:
Type:  Journal Article; Review     Date:  2010-07-17
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  74     ISSN:  1347-4820     ISO Abbreviation:  Circ. J.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-30     Completed Date:  2010-12-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1718-30     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Juntendo University, School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Asian Continental Ancestry Group
Cholesterol, LDL / blood*
Clinical Trials as Topic
Coronary Artery Disease / drug therapy*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use*
Hypolipidemic Agents
Plaque, Atherosclerotic
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Hypolipidemic Agents
Comments/Corrections
Comment In:
Circ J. 2010 Aug;74(8):1731-41   [PMID:  20671372 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heparin cofactor II attenuates vascular remodeling in humans and mice.
Next Document:  "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese p...